SCHEMBL15087103

SCHEMBL15087103

O=C(O)C1=C(c2ccccc2C(=O)Nc2ccc3c(c2)nc(O)c2ccccc23)CCC=C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.42
▸ KMT2A Q03164 7/20 0.42
▸ CYP2C9 P11712 4/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ATM Q13315 2/20 0.41
▸ LMNA P02545 1/20 0.39
▸ OPRL1 P41146 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ SOS1 Q07889 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ BLM P54132 1/20 0.37
▸ HIF1A Q16665 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15537236 0.83 MEN1 (0.58) MEN1KMT2ACYP2C9TDP1CYP1A2
SCHEMBL2583091 0.59 CYP2C9 (1.00) MEN1KMT2ACYP2C9TDP1CYP1A2
SCHEMBL30516131 0.59 CYP2C9 (1.00) MEN1KMT2ACYP2C9TDP1CYP1A2
SCHEMBL6769896 0.59 TP53 (0.54) MEN1KMT2AKDM4ELMNAOPRL1
SCHEMBL7607540 0.58 GPR3 (0.54) KMT2ATDP1CYP1A2CYP3A4KDM4E
SCHEMBL25149031 0.57 LMNA (1.00) MEN1KMT2ACYP2C9CYP3A4ATM
SCHEMBL1017795 0.57 CYP3A4 (0.89) MEN1KMT2ACYP2C9TDP1CYP3A4
SCHEMBL4654592 0.57 KMT2A (0.65) MEN1KMT2ALMNAPOLBNPC1
SCHEMBL3655566 0.57 DEGS1 (0.65) MEN1KMT2AKDM4ELMNAPOLB
SCHEMBL1458777 0.57 CHRNB2 (0.63) MEN1KMT2ACYP2C9CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969339-B2 Compositions and methods for bone formation and modeling ENZO BIOCHEM, INC. (US) 2015-03-03 — — US disclosed
US-8969339-B2 Compositions and methods for bone formation and modeling ENZO BIOCHEM, INC. (US) 2015-03-03 — — US disclosed
US-20130172332-A1 COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING ENZO BIOCHEM, INC. (US) 2013-07-04 — — US disclosed
US-20130172332-A1 COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING ENZO BIOCHEM, INC. (US) 2013-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172332-A1 COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING LRP6, BMP6, WNT3A MEN1 3827/4885KMT2A 4661/4885CYP2C9 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback